Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 25 of 25 matching drugs for ESR2 — including drugs targeting any of its 16 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
alendronate, etidronate, ibandronate, risedronate, raloxifene ESR2 Direct 2
genistein, erlotinib hydrochloride, gemcitabine hydrochloride ESR2 Direct 1
tamoxifen, etoposide ESR2 Direct 1
allylestrenol ESR2 Direct yes 0
bazedoxifene ESR2 Direct yes 0
bazedoxifene acetate ESR2 Direct yes 0
chlorotrianisene ESR2 Direct yes 0
cyclofenil ESR2 Direct yes 0
estetrol ESR2 Direct yes 0
estramustine phosphate ESR2 Direct yes 0
estramustine phosphate sodium ESR2 Direct yes 0
estriol ESR2 Direct yes 0
estropipate ESR2 Direct yes 0
fulvestrant ESR2 Direct yes 0
lasofoxifene ESR2 Direct yes 0
ospemifene ESR2 Direct yes 0
raloxifene ESR2 Direct yes 0
raloxifene hydrochloride ESR2 Direct yes 0
toremifene ESR2 Direct yes 0
toremifene citrate ESR2 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
ataluren RPL22 SSL via RPL22 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.